- Report
- July 2024
- 132 Pages
Global
From €880EUR$950USD£738GBP
- Newsletter
- September 2024
- 3 Pages
Global
From €121EUR$131USD£102GBP
- Report
- November 2021
- 802 Pages
Global
From €4631EUR$5,000USD£3,884GBP
- Report
- November 2021
- 1184 Pages
Global
From €5557EUR$6,000USD£4,661GBP
- Report
- November 2021
- 1165 Pages
Global
From €5557EUR$6,000USD£4,661GBP
- Report
- November 2021
- 747 Pages
Global
From €3705EUR$4,000USD£3,108GBP
- Report
- December 2023
- 219 Pages
Global
From €3307EUR$3,570USD£2,773GBP
- Report
- July 2023
- 382 Pages
Global
From €3307EUR$3,570USD£2,773GBP
- Report
- May 2024
- 140 Pages
Global
From €4630EUR$4,999USD£3,884GBP
- Report
- August 2024
- 150 Pages
Global
From €2315EUR$2,499USD£1,941GBP
- Report
- August 2024
- 200 Pages
Global
From €3704EUR$3,999USD£3,107GBP
- Report
- August 2024
- 200 Pages
Global
From €3704EUR$3,999USD£3,107GBP
- Report
- August 2024
- 150 Pages
Global
From €2315EUR$2,499USD£1,941GBP
- Report
- August 2024
- 150 Pages
Global
From €2315EUR$2,499USD£1,941GBP
- Report
- February 2024
- 180 Pages
Global
From €5093EUR$5,499USD£4,272GBP
- Report
- September 2023
- 160 Pages
Global
From €2778EUR$2,999USD£2,330GBP
T Cell Therapies are a type of biotechnology that involves the use of a patient's own T cells to treat diseases. T cells are a type of white blood cell that play a key role in the body's immune system. T Cell Therapies involve the extraction of T cells from a patient, engineering them to recognize and attack specific targets, and then reintroducing them into the patient's body. This type of therapy has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. It has also been used to treat autoimmune diseases, such as rheumatoid arthritis and Crohn's disease.
T Cell Therapies are a rapidly growing field of biotechnology, with many companies investing in research and development. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in developing and commercializing T Cell Therapies. Other companies, such as Gilead Sciences, Celgene, and Regeneron, are also investing in the field. Show Less Read more